Pulse Biosciences (NASDAQ:PLSE) Shares Gap Up – Should You Buy?

Pulse Biosciences, Inc. (NASDAQ:PLSE)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $17.40, but opened at $17.87. Pulse Biosciences shares last traded at $18.04, with a volume of 23,965 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded Pulse Biosciences to a “sell” rating in a research note on Tuesday.

Pulse Biosciences Stock Performance

The firm has a 50-day moving average price of $17.93 and a two-hundred day moving average price of $16.66.

Pulse Biosciences (NASDAQ:PLSE) last posted its earnings results on Wednesday, October 30th. The company reported ($0.21) EPS for the quarter. During the same quarter in the previous year, the firm earned ($0.19) EPS.

Insider Buying and Selling at Pulse Biosciences

In other Pulse Biosciences news, CEO Burke Thomas Barrett sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $17.42, for a total transaction of $871,000.00. Following the completion of the sale, the chief executive officer now directly owns 63,172 shares of the company’s stock, valued at $1,100,456.24. This represents a 44.18 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert W. Duggan bought 55,256 shares of the stock in a transaction on Friday, December 13th. The stock was bought at an average price of $17.18 per share, for a total transaction of $949,298.08. Following the completion of the purchase, the director now directly owns 42,328,717 shares in the company, valued at approximately $727,207,358.06. The trade was a 0.13 % increase in their position. The disclosure for this purchase can be found here. 71.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Pulse Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Franklin Resources Inc. purchased a new position in shares of Pulse Biosciences in the 3rd quarter valued at about $378,000. Barclays PLC boosted its stake in shares of Pulse Biosciences by 361.4% during the 3rd quarter. Barclays PLC now owns 30,306 shares of the company’s stock worth $530,000 after acquiring an additional 23,738 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Pulse Biosciences by 7.8% in the 3rd quarter. Geode Capital Management LLC now owns 457,165 shares of the company’s stock worth $8,020,000 after acquiring an additional 33,200 shares during the period. State Street Corp raised its holdings in Pulse Biosciences by 17.8% during the third quarter. State Street Corp now owns 461,333 shares of the company’s stock worth $8,092,000 after purchasing an additional 69,696 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in Pulse Biosciences during the third quarter worth $588,000. Institutional investors and hedge funds own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.